E

Euroapi SAS
PAR:EAPI

Watchlist Manager
Euroapi SAS
PAR:EAPI
Watchlist
Price: 3.112 EUR 0.39%
Market Cap: 297.5m EUR

Relative Value

The Relative Value of one EAPI stock under the Base Case scenario is 8.479 EUR. Compared to the current market price of 3.112 EUR, Euroapi SAS is Undervalued by 63%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

EAPI Relative Value
Base Case
8.479 EUR
Undervaluation 63%
Relative Value
Price
E
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
51
vs Industry
88
Median 3Y
0.4
Median 5Y
0.3
Industry
2.6
Forward
0.3
vs History
vs Industry
37
Median 3Y
-2.1
Median 5Y
-2.3
Industry
21.6
Forward
-22.2
vs History
44
vs Industry
52
Median 3Y
4.4
Median 5Y
4.2
Industry
16.5
vs History
vs Industry
25
Median 3Y
-1.6
Median 5Y
-1.8
Industry
22.5
vs History
66
vs Industry
79
Median 3Y
0.4
Median 5Y
0.4
Industry
2.3
vs History
57
vs Industry
89
Median 3Y
0.6
Median 5Y
0.5
Industry
2.9
Forward
0.3
vs History
57
vs Industry
73
Median 3Y
3.3
Median 5Y
2.8
Industry
5.5
vs History
31
vs Industry
49
Median 3Y
4.3
Median 5Y
3.7
Industry
13
Forward
4.1
vs History
vs Industry
3
Median 3Y
40.1
Median 5Y
38.2
Industry
16.6
Forward
-6.1
vs History
55
vs Industry
52
Median 3Y
5
Median 5Y
4.7
Industry
15.8
vs History
vs Industry
25
Median 3Y
-8.6
Median 5Y
-11.9
Industry
19.1
vs History
71
vs Industry
82
Median 3Y
0.4
Median 5Y
0.4
Industry
1.9

Multiples Across Competitors

EAPI Competitors Multiples
Euroapi SAS Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
FR
Euroapi SAS
PAR:EAPI
295.6m EUR 0.3 -2.4 5.2 -17.2
US
Eli Lilly and Co
NYSE:LLY
997.2B USD 16.8 54.2 36.3 39
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
US
Johnson & Johnson
NYSE:JNJ
503.6B USD 5.5 20 16.4 21.3
CH
Roche Holding AG
SIX:ROG
251.4B CHF 4.1 26.7 11.4 13.3
UK
AstraZeneca PLC
LSE:AZN
211.3B GBP 4.9 30.2 108.7 159.1
CH
Novartis AG
SIX:NOVN
206.9B CHF 4.6 18.1 11.5 14.8
US
Merck & Co Inc
NYSE:MRK
244.4B USD 3.8 12.8 9.2 10.9
DK
Novo Nordisk A/S
CSE:NOVO B
1.4T DKK 4.3 13.1 9.1 10.6
IE
Endo International PLC
LSE:0Y5F
209B USD 90.1 -71.5 331.1 830.4
US
Pfizer Inc
NYSE:PFE
145.2B USD 2.3 14.8 7.5 10.3
P/E Multiple
Earnings Growth PEG
FR
E
Euroapi SAS
PAR:EAPI
Average P/E: 23.7
Negative Multiple: -2.4
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
54.2
53%
1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
US
Johnson & Johnson
NYSE:JNJ
20
29%
0.7
CH
Roche Holding AG
SIX:ROG
26.7
29%
0.9
UK
AstraZeneca PLC
LSE:AZN
30.2
38%
0.8
CH
Novartis AG
SIX:NOVN
18.1
17%
1.1
US
Merck & Co Inc
NYSE:MRK
12.8
15%
0.9
DK
Novo Nordisk A/S
CSE:NOVO B
13.1
4%
3.3
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -71.5 N/A N/A
US
Pfizer Inc
NYSE:PFE
14.8
29%
0.5
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
FR
E
Euroapi SAS
PAR:EAPI
Average EV/EBITDA: 399.3
5.2
21%
0.2
US
Eli Lilly and Co
NYSE:LLY
36.3
33%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
US
Johnson & Johnson
NYSE:JNJ
16.4
9%
1.8
CH
Roche Holding AG
SIX:ROG
11.4
4%
2.9
UK
AstraZeneca PLC
LSE:AZN
108.7
10%
10.9
CH
Novartis AG
SIX:NOVN
11.5
6%
1.9
US
Merck & Co Inc
NYSE:MRK
9.2
6%
1.5
DK
Novo Nordisk A/S
CSE:NOVO B
9.1
2%
4.6
IE
E
Endo International PLC
LSE:0Y5F
331.1
N/A N/A
US
Pfizer Inc
NYSE:PFE
7.5
1%
7.5
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
FR
E
Euroapi SAS
PAR:EAPI
Average EV/EBIT: 1 881.2
Negative Multiple: -17.2
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
39
36%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
US
Johnson & Johnson
NYSE:JNJ
21.3
15%
1.4
CH
Roche Holding AG
SIX:ROG
13.3
5%
2.7
UK
AstraZeneca PLC
LSE:AZN
159.1
23%
6.9
CH
Novartis AG
SIX:NOVN
14.8
12%
1.2
US
Merck & Co Inc
NYSE:MRK
10.9
8%
1.4
DK
Novo Nordisk A/S
CSE:NOVO B
10.6
1%
10.6
IE
E
Endo International PLC
LSE:0Y5F
830.4
N/A N/A
US
Pfizer Inc
NYSE:PFE
10.3
8%
1.3